Drugs / ARO-DM1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06138743 | Mar 2024 → Dec 2026 expected | myotonic dystrophy type 1 | Arrowhead Pharmaceuticals | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-11-28 | Arrowhead Pharmaceuticals | Regulatory Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy arrowheadpharma.com ↗
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-DM1, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for type 1 myotonic dystrophy (DM1), the most common adult-onset muscular dystrophy. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-03-08 | Arrowhead Pharmaceuticals | Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy arrowheadpharma.com ↗ |
| 2023-11-28 | Arrowhead Pharmaceuticals | Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy arrowheadpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARO-DM1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06138743 ↗ |
| Route | Intravenous | “ARO-DM1 by intravenous (IV) infusion” NCT06138743 ↗ |